Last reviewed · How we verify
AAV BBP-631
At a glance
| Generic name | AAV BBP-631 |
|---|---|
| Sponsor | Adrenas Therapeutics Inc |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) (PHASE1, PHASE2)
- A Study to Determine Eligibility for CAH-301 (A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) [NCT04783181])
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AAV BBP-631 CI brief — competitive landscape report
- AAV BBP-631 updates RSS · CI watch RSS
- Adrenas Therapeutics Inc portfolio CI